Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental CAR T-Cell therapy takes on tough lymphoma

NCT ID NCT06534060

Recruiting now Disease control Sponsor: March Biosciences Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called MB-105 for people with a type of blood cancer called T-cell lymphoma that has come back or not responded to standard treatments. MB-105 is made from the patient's own immune cells, which are modified to better recognize and attack cancer cells. The trial will enroll 46 adults and measure safety and how well the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MB-105 (a CAR T-cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat T-cell lymphoma that has not responded to other therapies.
What could go wrong
This is an early-phase trial with only 46 participants, so results may not apply to everyone. CAR T-cell therapies can cause serious side effects like cytokine release syndrome and nervous system problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, T-CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma primary cutaneous T-cell non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, T-CELL

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030, United States

  • Cleveland Clinic

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Moffitt Cancer Center Magnolia Campus

    RECRUITING

    Tampa, Florida, 33612, United States

  • Oregan Health & Science University

    NOT_YET_RECRUITING

    Portland, Oregon, 97239, United States

  • SCRI - Colorado Blood Cancer Institute (CBCI)

    NOT_YET_RECRUITING

    Denver, Colorado, 92037, United States

  • University of Iowa

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • University of Nebraska

    RECRUITING

    Omaha, Nebraska, 68198, United States

  • University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • University of San Diego (UCSD)-Moores Cancer Center

    RECRUITING

    San Diego, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.